Cargando…
The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy
With the improvement of cancer therapy, survival related to malignancy has improved, but the prevalence of long-term cardiotoxicity has also increased. Cancer therapies with known cardiac toxicity include anthracyclines, biologic agents (trastuzumab), and multikinase inhibitors (sunitinib). The most...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Libertas Academica
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878717/ https://www.ncbi.nlm.nih.gov/pubmed/27257396 http://dx.doi.org/10.4137/BIC.S31798 |